HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metallothioneins may be a potential prognostic biomarker for tumors: A Prisma-compliant meta-analysis.

AbstractBACKGROUND:
Metallothioneins (MTs) were reported to be associated with many kinds of tumors' prognosis, although MTs expression varied greatly among tumors. To assess the prognostic value of Metallothioneins (MTs) in different kinds of tumors, comprehensive literature search was conducted to perform a meta-analysis.
METHODS:
Eligible studies were identified by PubMed, MEDLINE, Web of Science (WOS), the Cochrane Library of Systematic Reviews, EMBASE, China National Knowledge Infrastructure (CNKI), WANFANG database and SinoMed database up to December 2017, which was designed to assess the prognostic value of MTs in different kinds of tumors. The main endpoint events were overall survival (OS) and disease-free survival (DFS). Hazard ratios (HRs) and its variance were retrieved from the original studies directly or calculated using Engauge Digitizer version 4.1. Random or fixed effects model meta-analysis was employed depending on the heterogeneity. Publication bias was evaluated by funnel plots, Begg and Egger tests.
RESULTS:
A total of 22 studies were enrolled in this meta-analysis, including 2843 tumor tissues (1517 were MTs negative/low, and 1326 were MTs high). Results showed that there was significant association between MTs expression and tumors' OS (HR = 1.60; 95%CI 1.34∼1.92, P < .00001). Subgroup analysis showed that high level of MTs expression was associated with prolonged OS in liver cancer (HR = 0.65, 95%CI 0.48∼0.89, P = .007), but it was on the contrary in the tumor of ovary (HR = 1.47, 95%CI 1.01∼2.14, P = .04), bladder (HR = 1.71, 95%CI 1.21∼2.42, P = .002), intestine (HR = 3.13, 95%CI 1.97∼4.97, P < .00001), kidney (HR = 3.31, 95%CI 1.61∼6.79, P = .001). However, there was no significant association between MTs expression and OS in breast (HR = 1.02, 95%CI 0.69∼1.51, P = .93).
CONCLUSIONS:
MTs could be taken as a potential prognostic biomarker for tumors, and uniqueness of MTs prognostic value in liver cancer deserved further study.
AuthorsLei Wang, Fuli Xin, Nanping Lin, Yingchao Wang, Xiaolong Liu, Jingfeng Liu
JournalMedicine (Medicine (Baltimore)) Vol. 97 Issue 52 Pg. e13786 (Dec 2018) ISSN: 1536-5964 [Electronic] United States
PMID30593161 (Publication Type: Journal Article, Meta-Analysis)
Chemical References
  • Biomarkers, Tumor
  • Metallothionein
Topics
  • Biomarkers, Tumor (analysis)
  • Case-Control Studies
  • Disease-Free Survival
  • Female
  • Humans
  • Intestinal Neoplasms (metabolism, mortality)
  • Kaplan-Meier Estimate
  • Kidney Neoplasms (metabolism, mortality)
  • Liver Neoplasms (metabolism, mortality)
  • Male
  • Metallothionein (analysis)
  • Neoplasms (metabolism, mortality)
  • Ovarian Neoplasms (metabolism, mortality)
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Urinary Bladder Neoplasms (metabolism, mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: